What is the main business of Omniseptica?

The main business activity of Omniseptica focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 31, 2020.

Where is the headquarters located?

The headquarters is located at: Aleja Jana Pawła Ii 22, 00-133 Warszawa.

Who is on the management board?

The management board consists of: Marcin Łoś (Member of the Management Board) and Paweł Świerżewski (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from July 31, 2020 to December 31, 2020.

What revenue was generated?

In 2020, the company generated total revenue of $3,475.

Is the company profitable?

No, the company recorded a net loss of $4,039 in 2020.

What is the main operating cost?

The largest operating cost category falls under materials and energy. This category amounted to $1,614 in 2020, representing 21% of all operating expenses.

Omnisepticasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2020-07-31

Share capital

5 000,00 PLN

Activity description

Phage Consultants works on detecting, preventing, and troubleshooting bacteriophage contamination in bacterial fermentation bioprocesses. The company provides facility audits, consultations, staff training, bioprocess optimization, SOP improvement, new facility development, and routine or ad hoc sample testing. Its offer also includes cell bank testing, phage production and characterization, and contract research.

Registered address

Aleja Jana Pawła II 22, 00-133 Warszawa, Poland

Website

omniseptica.com

Financials

The financial statement for 2021 has not yet been filed with the Financial Document Repository (past deadline).

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2020.

Results vs industry

Revenue

This companyUSD 3.48kMedianUSD 38.31kAverageUSD 2.31m

Net profit

This companyUSD -4.04kMedianUSD -1.50kAverageUSD -84.98k

Operating costs

This companyUSD 7.51kMedianUSD 56.25kAverageUSD 2.29m

Assets

This companyUSD 4.55kMedianUSD 116.77kAverageUSD 2.72m

Industry

Bank accounts

Was a VAT taxpayer from 2020-10-01 to 2023-01-19. Removed from VAT register

Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)

Debt

1 closed proceeding recorded in KRZ history. Closed proceedings in history

Registration date	Proceeding type	Status
Jul 10, 2025	Discontinued enforcement proceedings	Closed

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Authorized Representatives

Marcin Łoś — Management Board Member

Paweł Świerżewski — Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Marcin Łoś (50)	50	$675.31	50%
Paweł Świerżewski (51)	50	$675.31	50%

Beneficial owners

No beneficial owners recorded for the company Omniseptica.

Competitors

Name	Revenue	Website
Micropurasp. z o.o.	$12,556.50	micropura.eu
Microbiota Medsp. z o.o.	$7,423.69	microbiota-med.com
Jotachemsp. z o.o.	$6,512.58	jotachem.pl
Fusiomicasp. z o.o.	$5,263.98	fusiomica.com
Passio Human Microbiomesp. z o.o.	$1,856.58	passiohumanmicrobiome.com

FAQ

Last updated: 2026-04-20